With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
AI Collaboration to Design Universal Vaccines for Tropical Diseases
Nagasaki University and NEC OncoImmunity (NOI), a leading artifi cial intelligence (AI) company, have announced their collaboration to utilise NOI’s AI platform in the creation of universal vaccines against highly pathogenic and tropical infectious diseases.
The joint effort between NOI and Nagasaki University aims to leverage advanced AI capabilities to optimise vaccine designs for broad protection against specifi c pathogen families prevalent in tropical regions. Within this partnership, NOI’s AI technology will design both T cell and B cell vaccines, with Nagasaki University validating the designs using their ‘wet-lab’ expertise and donor samples collected from their extensive network of tropical fi eld stations.
Additionally, this collaboration has established the Vaccine Informatics Department at Nagasaki University’s Institute of Tropical Medicine. Led by Dr Trevor Clancy, Chief Scientifi c Offi cer of NOI, this department will utilise AI technology to support Nagasaki University’s research on understanding immune protection correlations across various tropical diseases. NEC’s AI drug development team members will also be part of this department.
Professor Takeshi Nagayasu, MD, PhD, Trustee (Strategic Development and Research), Nagasaki University: “We are delighted to embark on this collaboration with NEC OncoImmunity in our pursuit of designing universal vaccines targeting tropical infectious diseases.
By combining the expertise of Nagasaki University in tropical medicine with the advanced AI technology of NEC, we aim to make signifi cant strides in vaccine development for the benefi t of global health.”
Richard Stratford, CEO of NOI, expressed his enthusiasm about the collaboration, stating: “NOI’s core AI technology is well suited for the development of universal vaccines, and we are fully committed to delivering effective vaccine designs to Nagasaki University that target highly pathogenic and tropical infectious diseases. We are immensely proud of this collaboration with such a world- renowned tropical medicine institute, and we anticipate signifi cant outcomes from this project.”
Masamitsu Kitase, Corporate Senior VP, Head of the Healthcare and Life Science Division, NEC Corporation, commented: “The NEC Group is very excited by this collaboration with Nagasaki University, which will demonstrate interdisciplinary research between computer technology and knowledge for Tropical Medicine, and promises to make signifi cant contributions to vaccine development. Infectious diseases have gained even more attention following the recent pandemic, and NEC is committed to using its state-of-art AI technology to develop effective vaccines in this space.”
More information online:
ilmt.co/PL/Keyb 61089pr@reply-direct.com
New Integrated Biology Centre to Boost Malaysian Research Capabilities
Agilent Technologies Inc has unveiled its newest Integrated Biology Center at Monash University in Malaysia, aimed at boosting local research capabilities in the fi eld of science. The inauguration coincided with the company’s Academia-Industrial Day 2023, attended by distinguished guests from the research community.
Situated within the university’s Jeffrey Cheah School of Medicine and Health Sciences at Sunway, the centre is fully equipped with the company’s advanced liquid chromatography and mass spectrometry (LC/MS) and gas chromatography (GC/MS) systems. It is poised to offer analytical expertise for applied biology research, potentially leading to publications and clinical applications.
This latest centre marks the third centre of excellence (CoE) established through a longstanding collaboration between Agilent and Monash University. Previous collaborations resulted in a genomic research lab in 2011 and a proteomics and metabolomics platform in 2016.
Professor Dato’ Dr Adeeba Kamarulzaman, President and Pro Vice-Chancellor of Monash University Malaysia, expressed: “With Agilent’s cutting-edge technologies and expertise, this centre will accelerate breakthroughs in applied biology research and its potential clinical applications. We look forward to fostering industry collaborations and making signifi cant contributions to the scientifi c community in Malaysia and beyond.”
Patent Explores Therapeutic use of Arsenic and Metal Ions
diseases. The European Patent Offi ce (EPO) granted similar protection (EP3972613) in April 2023.
These intellectual property rights pave the way for clinical and commercial developments by the company and interested partners in two main immediate areas of application; immune and autoimmune related diseases such as chronic Graft-versus-Host Diseases (cGvHD), systemic sclerosis and systemic lupus erythematosus, and also in oncology, where ATO has already demonstrated exceptional results for patients, including complete remission of acute promyelocytic leukaemia.
A key new patent the ‘Use of metal ions to potentiate the therapeutic effects of arsenic’ has been issued to clinical-stage company BioSenic by the China National Intellectual Property Administration (CNIPA). The patent (ZL202080040613.1) covers the use of its ATO platform in combination with metal ions such as copper, which has the potential to improve the treatment of autoimmune
“BioSenic’s new patent in China opens up new avenues of industrial development for the treatment of diseases with clinical unmet medical needs in the fi eld of cancer, autoimmunity and infectious diseases, in Asia and elsewhere,” said François Rieger, PhD, Chairman and Chief Executive Offi cer of BioSenic. “We are thrilled to open up new chapters in the continuous worldwide effort in trying to control lethal diseases with no real cure.”
More information online:
ilmt.co/PL/KeME 61272pr@reply-direct.com
Chai Meng Fee, Agilent Malaysia General Manager, added: “The addition of the Integrated Biology Centre strengthens our expanding presence locally and provides scientists with greater support for their research across Malaysia.”
Providing competency training for its lab professionals, the centre also opens avenues for Agilent and Monash University to explore partnerships with start- ups, academia and other laboratories in Malaysia. Currently, Agilent has a 200,000 ft2 facility in Penang, manufacturing key products for its spectroscopy line, diagnostics and genomics, and vacuum pump division, along with a sales offi ce located in Petaling Jaya, Selangor, Malaysia.
More information online:
ilmt.co/PL/380W 61108pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
